"* Abbott (NYSE:ABT) announces that the FDA has issued Emergency Use Authorization for its molecular test that can detect a positive coronavirus diagnosis in as little as five minutes and a negative result in 13 minutes.
* The test runs on Abbott's point-of-care ID Now platform, a portable instrument that can be used in almost any healthcare setting.
* The ID NOW COVID-19 tests will be available next week, and Abbott expects to ramp up manufacturing to deliver 50,000 tests per day by April 1."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.